JP4041123B2 - 新規なジアザビシクロノネン - Google Patents

新規なジアザビシクロノネン Download PDF

Info

Publication number
JP4041123B2
JP4041123B2 JP2004501406A JP2004501406A JP4041123B2 JP 4041123 B2 JP4041123 B2 JP 4041123B2 JP 2004501406 A JP2004501406 A JP 2004501406A JP 2004501406 A JP2004501406 A JP 2004501406A JP 4041123 B2 JP4041123 B2 JP 4041123B2
Authority
JP
Japan
Prior art keywords
phenyl
diazabicyclo
propyl
ene
carboxylic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2004501406A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005527602A5 (https=
JP2005527602A (ja
Inventor
ベゼンコン オリヴィエー
バー ダニエル
フィシュリ ウォルター
リーメン ルボス
リチャードービルドステイン シルヴィア
ウェーバー ハンスーピーター
ウィーラー トーマス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Actelion Pharmaceuticals Ltd
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29286070&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP4041123(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of JP2005527602A publication Critical patent/JP2005527602A/ja
Publication of JP2005527602A5 publication Critical patent/JP2005527602A5/ja
Application granted granted Critical
Publication of JP4041123B2 publication Critical patent/JP4041123B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2004501406A 2002-04-29 2003-04-08 新規なジアザビシクロノネン Expired - Fee Related JP4041123B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP0204705 2002-04-29
PCT/EP2003/003721 WO2003093267A1 (en) 2002-04-29 2003-04-08 7-aryl-3,9-diazabicyclo(3.3.1)non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension, cardiovascular or renal diseases

Publications (3)

Publication Number Publication Date
JP2005527602A JP2005527602A (ja) 2005-09-15
JP2005527602A5 JP2005527602A5 (https=) 2006-06-01
JP4041123B2 true JP4041123B2 (ja) 2008-01-30

Family

ID=29286070

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004501406A Expired - Fee Related JP4041123B2 (ja) 2002-04-29 2003-04-08 新規なジアザビシクロノネン

Country Status (26)

Country Link
US (2) US7427613B2 (https=)
EP (1) EP1501830B1 (https=)
JP (1) JP4041123B2 (https=)
KR (1) KR100783863B1 (https=)
CN (1) CN1649870A (https=)
AT (1) ATE527261T1 (https=)
AU (1) AU2003233963B2 (https=)
BR (1) BR0309498A (https=)
CA (1) CA2483241C (https=)
CL (1) CL2003002042A1 (https=)
CO (1) CO5631443A2 (https=)
EC (1) ECSP045378A (https=)
ES (1) ES2372931T3 (https=)
HR (1) HRP20041132A2 (https=)
IL (1) IL164767A0 (https=)
IS (1) IS7545A (https=)
MA (1) MA27305A1 (https=)
MX (1) MXPA04010608A (https=)
NO (1) NO20045042L (https=)
NZ (1) NZ536750A (https=)
PL (1) PL372141A1 (https=)
RU (1) RU2343153C2 (https=)
TW (1) TW200514786A (https=)
UA (1) UA80821C2 (https=)
WO (1) WO2003093267A1 (https=)
ZA (1) ZA200408283B (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004096804A1 (en) * 2003-04-28 2004-11-11 Actelion Pharmaceuticals Ltd Diazabicyclononene and tetrahydropyridine derivatives as renin inhibitors
AU2004233575A1 (en) * 2003-04-30 2004-11-11 Actelion Pharmaceuticals Ltd 9-azabicyclo'3.3.1!non-6-ee derivatives with a heteroatom at the 3-position as renin inhibitors
JP2006524657A (ja) * 2003-04-30 2006-11-02 アクテリオン　ファマシューティカルズ　リミテッド 新規トロパン誘導体
US20060235044A1 (en) * 2003-04-30 2006-10-19 Olivier Bezencon Azabicyclononene derivatives
JP2006525259A (ja) * 2003-05-02 2006-11-09 アクテリオン　ファマシューティカルズ　リミテッド 新規ジアザビシクロノネン誘導体
WO2004105762A1 (en) * 2003-05-30 2004-12-09 Actelion Pharmaceuticals Ltd Medical use of diazabicyclononene derivatives as inhibitors of parasite aspartic proteases
CN1863773A (zh) * 2003-10-09 2006-11-15 埃科特莱茵药品有限公司 四氢吡啶衍生物
EP1678176A1 (en) * 2003-10-13 2006-07-12 Actelion Pharmaceuticals Ltd. Diazabicyclononene derivatives and their use as renin inhibitors
CN1930170A (zh) * 2003-10-23 2007-03-14 埃科特莱茵药品有限公司 二氮杂二环壬烯及四氢吡啶衍生物用作肾素抑制剂
WO2005054243A1 (en) * 2003-12-05 2005-06-16 Actelion Pharmaceuticals Ltd Diazabicyclononene derivatives and their use as renin inhibitors
US20070135406A1 (en) * 2003-12-05 2007-06-14 Olivier Bezencon Diazabicyclononene and tetrahydropyridine derivatives with a new side-chain
EP1786814B1 (en) * 2004-08-25 2010-03-31 Actelion Pharmaceuticals Ltd. Bicyclononene derivatives as renin inhibitors
WO2006021403A1 (en) * 2004-08-25 2006-03-02 Actelion Pharmaceuticals Ltd Bicyclononene derivatives
WO2006021401A2 (en) * 2004-08-25 2006-03-02 Actelion Pharmaceuticals Ltd Bicylononene derivatives
WO2006021399A2 (en) * 2004-08-25 2006-03-02 Actelion Pharmaceuticals Ltd Azabicyclononene derivatives as renin inhibitors
AR052263A1 (es) * 2004-12-08 2007-03-07 Actelion Pharmaceuticals Ltd Derivado de diazabiciclononeno
WO2006063610A1 (en) * 2004-12-17 2006-06-22 Actelion Pharmaceuticals Ltd Heteroaryl substituted diazabicyclononene derivatives
GB0428526D0 (en) 2004-12-30 2005-02-09 Novartis Ag Organic compounds
CA2595986A1 (en) * 2005-01-28 2006-08-03 Actelion Pharmaceuticals Ltd 7-{4-[2-(2,6-dichlor0-4-methylphenoxy)-ethoxy]phenyl}-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid cyclopropyl-(2,3-dimethylbenzyl)amides as inhibitors of renin for the treatment of hypertension
EP1893578A2 (en) * 2005-05-27 2008-03-05 Actelion Pharmaceuticals Ltd. Novel piperidine carboxylic acid amide derivatives
GB0514203D0 (en) 2005-07-11 2005-08-17 Novartis Ag Organic compounds
JP5306821B2 (ja) 2005-12-30 2013-10-02 ノバルティス アーゲー レニン阻害剤としての３，５−置換ピペリジン化合物
NZ570828A (en) 2006-02-02 2011-07-29 Actelion Pharmaceuticals Ltd Secondary amines as renin inhibitors
AU2007224368A1 (en) * 2006-03-08 2007-09-13 Actelion Pharmaceuticals Ltd New amines
JP2010527942A (ja) 2007-05-24 2010-08-19 メルク フロスト カナダ リミテツド 新規類のレニン阻害剤
NZ582098A (en) 2007-06-25 2012-03-30 Novartis Ag N5-(2-ethoxyethyl)-n3-(2-pyridinyl)-3,5-piperidinedicarboxamide derivatives for use as renin inhibitors
AU2008288648A1 (en) 2007-08-20 2009-02-26 Merck Frosst Canada Ltd. Renin inhibitors
CN102015682B (zh) 2008-05-05 2014-07-16 埃科特莱茵药品有限公司 作为肾素抑制剂的3,4-取代的哌啶衍生物
CN109721613B (zh) * 2017-10-27 2021-07-30 四川科伦博泰生物医药股份有限公司 含季铵离子的大环酰胺化合物及其药物组合物和用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3509161A (en) 1967-07-10 1970-04-28 Boehringer & Soehne Gmbh 3-phenyl-granatene-(2)-derivatives
GB9020927D0 (en) 1990-09-26 1990-11-07 Beecham Group Plc Pharmaceuticals
US5268361A (en) * 1991-06-07 1993-12-07 Sri International Hydroxyazido derivatives and related compounds as renin inhibitors
US5374719A (en) * 1993-06-04 1994-12-20 Eli Lilly And Company Process for converting loracarbef dihydrate to loracarbef monohydrate
RU2167865C2 (ru) * 1995-09-07 2001-05-27 Ф. Хоффманн-Ля Рош Аг Производные пиперидина, способ их получения, фармацевтическая композиция на их основе и промежуточные вещества
EP0966464B1 (en) 1997-03-03 2003-05-28 Basilea Pharmaceutica AG Substituted 2,4-diaminopyrimidines
US20060223795A1 (en) * 2003-05-02 2006-10-05 Oliver Bezencon Novel diazabicyclononene derivatives
WO2005054243A1 (en) * 2003-12-05 2005-06-16 Actelion Pharmaceuticals Ltd Diazabicyclononene derivatives and their use as renin inhibitors

Also Published As

Publication number Publication date
HRP20041132A2 (en) 2006-07-31
EP1501830A1 (en) 2005-02-02
US20080312242A1 (en) 2008-12-18
CO5631443A2 (es) 2006-04-28
ATE527261T1 (de) 2011-10-15
MXPA04010608A (es) 2004-12-13
IS7545A (is) 2004-11-22
US20050176700A1 (en) 2005-08-11
AU2003233963A1 (en) 2003-11-17
TW200514786A (en) 2005-05-01
KR100783863B1 (ko) 2007-12-10
ECSP045378A (es) 2004-11-26
IL164767A0 (en) 2005-12-18
BR0309498A (pt) 2005-02-15
RU2004134320A (ru) 2005-08-27
RU2343153C2 (ru) 2009-01-10
US7427613B2 (en) 2008-09-23
NO20045042L (no) 2004-11-19
ES2372931T3 (es) 2012-01-27
WO2003093267A1 (en) 2003-11-13
CN1649870A (zh) 2005-08-03
UA80821C2 (en) 2007-11-12
EP1501830B1 (en) 2011-10-05
ZA200408283B (en) 2006-05-31
KR20040101546A (ko) 2004-12-02
NZ536750A (en) 2007-02-23
MA27305A1 (fr) 2005-05-02
CA2483241A1 (en) 2003-11-13
PL372141A1 (en) 2005-07-11
AU2003233963B2 (en) 2008-09-11
CL2003002042A1 (es) 2005-02-04
CA2483241C (en) 2011-05-31
JP2005527602A (ja) 2005-09-15

Similar Documents

Publication Publication Date Title
JP4041123B2 (ja) 新規なジアザビシクロノネン
AU2003277285B2 (en) PGD2 receptor antagonists for the treatment of inflammatory diseases
CN114867727A (zh) Tau蛋白靶向化合物及相关使用方法
US5668132A (en) HIV Protease inhibitors useful for the treatment of AIDS
CN102573471B (zh) 新的吡咯烷衍生的β3肾上腺素受体激动剂
TWI711615B (zh) 作為可溶性鳥苷酸環化酶活化劑的雜環羧酸
TWI466877B (zh) 雙環式化合物及其醫藥用途
JP2005532371A (ja) レニン阻害剤としての新規なテトラヒドロピリジン誘導体
UA72611C2 (uk) Похідні заміщеного піролопіридинону, корисні як інгібітори фосфодіестерази
JP2014518267A (ja) 細菌感染症の治療のための架橋二環式化合物
IL293389A (en) New thyroid erasers
CN113784950A (zh) 新型拟甲状腺素药
JP2024531694A (ja) Ａｈｒアゴニスト
JP2006525259A (ja) 新規ジアザビシクロノネン誘導体
JP2010524891A (ja) 抗菌剤としての三環系化合物
JP2006524655A (ja) ３−位にヘテロ原子を有する新規９−アザビシクロノネン誘導体
RU2382041C2 (ru) Новые сложные эфиры кватернизованного хинуклидина
WO2023051628A1 (zh) 一类具有吡啶并六元环结构的sos1抑制剂
JP2006524654A (ja) 新規アザビシクロノネン誘導体
JP2007513107A (ja) ジアザビシクロノネンおよび新側鎖を有するテトラヒドロピリジン誘導体
JP4297972B2 (ja) 新規なピペリジンカルボン酸アミド誘導体
JP2006524657A (ja) 新規トロパン誘導体
JP2008510755A (ja) ビシクロノネン誘導体
JP2007509099A (ja) 新規ジアザビシクロノネンおよび新規極性側鎖を有するテトラヒドロピリジン誘導体
JP2007513106A (ja) 新規ジアザビシクロノネン誘導体およびその使用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060405

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060405

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20060814

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20060831

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20060929

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070302

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070604

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070629

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070918

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20071017

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20071108

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20101116

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100218

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20100218

A072 Dismissal of procedure [no reply to invitation to correct request for examination]

Free format text: JAPANESE INTERMEDIATE CODE: A072

Effective date: 20100616

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20101015

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20111116

Year of fee payment: 4

A072 Dismissal of procedure [no reply to invitation to correct request for examination]

Free format text: JAPANESE INTERMEDIATE CODE: A072

Effective date: 20110126

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121116

Year of fee payment: 5

LAPS Cancellation because of no payment of annual fees